Levosimendan for patients with heart failure undergoing major oncological surgery: A randomised blinded pilot study.

ABSTRACT:

Background and aims

Cardiovascular diseases and cancer are among the leading causes of mortality worldwide. The aim of this study is to evaluate the efficacy and safety of preoperative administration of levosimendan in patients with chronic heart failure (CHF) scheduled for major abdominal oncologic surgery.

Methods

This study included 60 patients with abdominal malignancy, ejection fraction (EF) <35% and CHF scheduled for surgery under isoflurane-fentanyl anaesthesia and were managed in the surgical intensive care unit perioperatively. They were randomised to receive levosimendan infusion (n = 30) at a dose of 0.1 μg/kg/min or placebo (n = 30) for 24 hours before surgery.

Results

The risk of hypotension (RR: 0.40, 95% CI: 0.19-0.83) or decompensated hea

SUBMITTER: Shaker EH 

PROVIDER: S-EPMC6921323 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature